The anti-PD-L1 monoclonal antibody atezolizumab in combination with bevacizumab is found to have antitumor activity with good tolerability in patients with metastatic renal cell carcinoma (258, 259), hepatocellular carcinoma (260), metastatic NSCLC without targetable mutations in association with chemotherapy (261) and metastatic NSCLC which fails to respond to atezolizumab monotherapy (262). The gene discussed is CD274; the disease is hepatocellular carcinoma.